Dr. George Nikopoulos, CEO and President of Mannin Research Inc. will participate in a BioPharma Dealmakers webcast, sponsored in part by Mannin Research Inc., featuring three companies innovating in therapies for eye disorders.
Please register here to participate > Webcast registration link
This webcast will explore some of the latest advances in the ophthalmic field through discussion with representatives from companies developing a range of innovative therapies for eye disorders, including the use of iPS cells, eye drops to deliver small-molecule drugs and complement inhibition.
The webcast will conclude with a live roundtable discussion and a Q&A section to allow you to participate and put your own questions to the speakers.
Dr. Nikopoulos has worked with and advised a number of biotechnology, pharmaceutical and med-tech companies. Dr. Nikopoulos' expertise includes translating complex technologies and innovations into strategies for commercialization, market research, and business development as well as pre-clinical toxicology study design.
Other webcast participants include:
· Hardy TS Kagimoto, MD, President, Representative Director and CEO of HEALIOS K.K.
· Dr. George Nikopoulos, CEO & President of Mannin Research Inc.
· Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers. Raveena has worked in the biopharma industry for over 10 years specifically in the areas of dealmaking, partnering and licensing.
More information can be found on the following social media links
About the Webcast
BioPharma Dealmakers webcasts are dedicated to small and large companies looking for commercial partnerships. Read the quarterly BioPharma Dealmakers supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
About Mannin Research Inc.
Mannin Research Inc. (Mannin), is a privately held, research stage biotechnology company, founded in July, 2012. Mannin is focused on the discovery, development, and commercialization of first-in-class therapeutics for vascular diseases using the Tie2 mechanism of action. Mannin's research is led by Chief Scientific Officer, Dr. Susan Quaggin, Chief of Nephrology and Director of the Feinberg Institute at Northwestern University.
With a formal research partnership with Northwestern University, revenue generating research and development and licensing agreement with QBioMed (OTCQB: QBIO), Mannin is leading the development of a new class of compounds for a range of vascular diseases. Our primary program, MAN-01, is for treatment of Primary Open-Angle Glaucoma.
More information is available at http://mannin.ca/.
Contact: email@example.com, +1-416-775-9767
About Q BioMed Inc.
Q BioMed Inc."Q" is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital the need to ensure they meet their developmental potential, enabling them to provide products to patients in need.
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. Further, in the event that the company with which we have recently signed a license/acquisition agreement subject to conditions fails to satisfy such conditions by closing, we will not proceed with the transaction. Other than update the status of the the aforementioned license/acquisition, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:Denis Corin, CEO, Q BioMed Inc., +1-888-357-2435
SOURCE Q BioMed Inc